Table 1 Clinical characteristics in the CHD patients and Controls (page 8, l. 204)
CHD patients | Controls | p value | |
|---|---|---|---|
Age (years) | 66.5 (62,71.8) | 69 (63, 71.5) | |
Male (%) | 40 (76.9%) | 11 (50%) | 0.04 |
Smoker (previous/current) | 31 (59.6%) | 10 (45.5%) | |
Weight (Kg) | 85 (70.3, 95.5) | 82.5 (77.5, 107.0) | |
Height (m) | 1.77 (1.68, 1.81) | 1.75 (1.67, 1.82) | |
Waist (cm) | 92 (86, 98) | 90 (88, 101) | |
BMI (kg/m2) | 27.3 (23.8, 30.1) | 28.4 (24.6, 31.6) | |
SBP (mmHg) | 140 (125, 160) | 140 (115, 163) | |
DBP (mmHg) | 80 (70, 87) | 79 (70, 86) | |
Cardiovascular status | |||
Previous AMI (%) | 20 (38.5%) | 2 (9.1%) | 0.025 |
Angina (%) | 24 (46.2%) | 0 (0%) | < 0.001 |
PCI (%) | 20 (38.5%) | 0 (0%) | 0.002 |
Hypertension (%) | 28 (53.9%) | 9 (40.9%) | |
Diabetes type I and II (%) | 14 (26.9%) | 3 (13.6%) | |
Heart failure (%) | 3 (5.8%) | 1 (4.5%) | |
Medications | |||
Aspirin (%) | 45 (86.5%) | 9 (40.9%) | < 0.001 |
Other antiplatelet (%) | 14 (26.9%) | 0 (0%) | |
ACEi/ATII (%) | 24 (46.2%) | 11 (50%) | |
Beta-blockers (%) | 32 (61.5%) | 6 (27.3%) | 0.015 |
Statins (%) | 37 (71.2%) | 11 (50%) | |
Other lipid-lowering agents (%) | 10 (19.2%) | 1 (4.5%) | |
Insulin (%) | 6 (11.5%) | 0 (0%) | |
Anti-diabetic drugs (%) | 11 (21.2%) | 3 (13.6%) | |
Diuretics (%) | 7 (13.5%) | 5 (22.7%) | |
Laboratory values | |||
hsCRP (mg/L) | 0.91 (0.49, 1.77) | 1.00 (1.00, 2.00) | |
Troponin T (ng/L) | 13 (9, 22) | 11.5 (9, 25) | |
TC (mmol/L) | 3.1 (2.7, 3.4) | 3.9 (2.8, 4.6) | 0.026 |
HDL-C (mmol/L) | 0.97 (0.75, 1.12) | 1.10 (0.87, 1.30) | |
LDL-C (mmol/L) | 1.83 (1.4, 2.2) | 2.18 (1.8, 2.9) | 0.02 |
Triglycerides (mmol/L) | 1.22 (1.0, 1.8) | 1.02 (0.9, 1.7) | |
Glucose (mmol/L) | 5.6 (4.9, 6.6) | 5.6 (4.9, 6.3) | |
HbA1c (mmol/mol) | 39 (36, 51) | 36 (33, 38) | 0.011 |
GFR (%) | 90 (75, 95) | 80 (68, 91) | 0.03 |
Creatinine (μmol/L) | 76 (67, 85) | 80 (64.8, 91) | |
Uric acid (μmol/L) | 313 (271, 362) | 317 (258, 396) | |